Christian Friedrich

No ORCID on file · 2 papers in corpus · active 2022-2024

Study types

  • rct 2

Condition tags

  • endometriosis 2
rct 2024
P2X3 Receptor Antagonist Eliapixant in Phase I Clinical Trials: Safety and Inter-ethnic Comparison of Pharmacokinetics in Healthy Chinese and Japanese Participants
Clinical pharmacokinetics ·doi:10.1007/s40262-024-01387-y

BACKGROUND: Afferent neuronal hypersensitization via P2X3 receptor signaling has been implicated as a driver of several disorders, including refractory chronic cough, endometriosis, diabetic neuropathic pain, and overactive bladder. Eliapix…

rct 2022
First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics
British journal of clinical pharmacology ·doi:10.1111/bcp.15358

AIMS: Neuronal hypersensitisation due to adenosine triphosphate-dependent P2X3 receptor signalling plays a significant role in several disorders including chronic cough and endometriosis. This first-in-human study of eliapixant (BAY 1817080…